COL18A1 and nasopharyngeal carcinoma: The exception to this pattern is the case of nasopharyngeal carcinoma, in which endostatin treatment correlates only with a better ORR at 3 months, but this does not translate into an improvement in long-term survival parameters, according to a phase II clinical trial performed by Li Y et al. [77].